GW Insists Sativex Is Approvable In U.K. Despite Phase III Failure In MS Pain
This article was originally published in The Pink Sheet Daily
Executive Summary
British pharma pulls application for MS spasticity but says it will re-file in U.K. after confirmatory study.
You may also be interested in...
GW Licenses U.S. Sativex Rights To Otsuka In $273 Million Deal
Firms plan to enter a longer-term collaboration later this year to discover novel cannabinoids for use in pain and central nervous system disorders.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.